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Resistance to many antimalaria drugs developed 
on the Cambodia–Thailand border long before develop-
ing elsewhere. Because antimalaria resistance is now a 
global problem, artemisinin-based combination therapies 
(ACTs) are the ﬁ  rst-line therapies in most malaria-endemic 
countries. However, recent clinical and molecular studies 
suggest the emergence of ACT-resistant Plasmodium fal-
ciparum infections in the Cambodia–Thailand border area, 
where standard ACT is artesunate and meﬂ  oquine. These 
ACT failures might be caused by high-level meﬂ  oquine re-
sistance because meﬂ   oquine was used for monotherapy 
long before the introduction of ACT. This observation raises 
2 questions. First, how can existing P. falciparum–resistant 
strains be controlled? Second, how can the evolution of new 
ACT- resistant strains be avoided elsewhere, e.g., in Africa? 
Enforcement of rational drug use and improved diagnostic 
capacity are among the measures needed to avoid and con-
tain ACT resistance.
A
rtemisinin-based combination therapies (ACTs), con-
sidered the best current treatment for falciparum ma-
laria (1), have energized worldwide programs to control 
malaria. Combination therapies, in general, tend to delay 
the development of microbial resistance. However, several 
ACT regimens are combinations of artesunate and older 
antimalarial drugs against which resistance already exists. 
Preexisting resistance to these older partner drugs could 
lead to drug failure. This may have already happened on 
the Cambodia–Thailand border (2).
Historical Perspective
The western Cambodia–southeastern Thailand bor-
der, which comprises the areas around the town of Pailin 
in Cambodia and the provinces of Trat and Chanthaburi in 
Thailand, has been an epicenter of drug-resistant malaria 
(3) (Figure). Resistance to chloroquine and sulfadoxine-
pyrimethamine occurred there in the late 1950s and 1960s, 
respectively. Meﬂ  oquine was introduced there in 1983, ﬁ  rst 
on the Thai side and in the form of meﬂ  oquine in com-
bination with sulfadoxine-pyrimethamine. Meﬂ  oquine 
resistance led to replacement by artesunate-meﬂ  oquine in 
Thailand in 1995. In Chanthaburi and Trat Provinces, con-
sidered by the Thai national malaria control program to be 
the areas with the highest level of meﬂ  oquine resistance, 
the dosages were 12 mg/kg artesunate and 25 mg/kg me-
ﬂ  oquine or a maximum adult dose of 600 mg artesunate 
and 1,250 mg meﬂ  oquine, given for 2 days. This regimen 
was 99% efﬁ  cacious when ﬁ  eld tested in the same border 
areas in 1993 (4). It also ensured better compliance than 
an extended (3-day) regimen. With the exception of the 
southeastern border of Thailand with Cambodia, the regi-
men remained effective throughout Thailand even when 
the control program switched to a 3-day treatment course 
in 2007 in accordance with the World Health Organization 
(WHO) recommendation.
In Cambodia in 2000, artesunate-meﬂ  oquine became 
the ﬁ  rst-line drug for the treatment of falciparum malaria. 
The dosages were 12 mg/kg artesunate and 20 mg/kg me-
ﬂ  oquine, or a maximum adult dose of 600 mg artesunate 
and 1,000 mg meﬂ  oquine, given for 3 days, in accordance 
with the WHO recommendation. The lower meﬂ  oquine 
dose was based on the perception that Cambodians were 
slightly smaller than Thais in body build. Malaria control 
programs of each country regularly monitor antimalarial 
therapeutic efﬁ  cacy at selected sentinel sites.
Resistance to Artesunate-Meﬂ  oquine 
Emerging resistance is supported by 3 independently 
conducted studies. In Pailin in 2002, clinical monitoring 
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of response to combination artesunate (≈12 mg/kg) and 
meﬂ  oquine (≈20 mg/kg) co-blister packs (artesunate for 
3 days and meﬂ  oquine for 1 day) showed 85.7% efﬁ  cacy 
at day 28 follow-up (5) (Table). A repeat study in Pailin 
in 2004, which used the same drug combination but more 
precise dosing and follow-up at 42 days, found efﬁ  cacy to 
be 79.3% (5). To exclude cases of reinfection from analy-
sis, parasite variants were identiﬁ  ed by using nested PCR 
ampliﬁ  cation of 3 polymorphic genes for merozoite surface 
protein 1 (msp1), msp2, and glutamate-rich protein (7). In 
Thailand’s Trat Province in 2003, efﬁ  cacy of 78.6% (95% 
conﬁ  dence interval 66.4%–91.1%) was reported from a 28-
day follow-up study of 44 patients who received the same 
total dosage of this combination in a 2-day regimen (6).
Each of the 3 studies used directly observed therapy, 
followed the WHO standard in vivo study protocol, and ob-
tained from their respective national control programs reli-
able drugs that worked effectively at other sentinel sites. 
Although each of the 3 studies was small, in aggregate they 
attest to a worrisome level of in vivo artesunate-meﬂ  oquine 
resistance.
The above clinical observations are supported by mo-
lecular evidence. High copy numbers of the Plasmodium 
falciparum multidrug resistance 1 (pfmdr1) gene, a marker 
of multidrug resistance (8), predicted recrudescence in the 
2004 Pailin study, even after PCR correction and adjust-
ment for age and parasite density (9). Thus, clinical and 
molecular evidence indicate that artesunate-meﬂ  oquine 
failures are occurring on the Cambodia–Thailand border. 
In contrast, artesunate-meﬂ   oquine remains effective in 
eastern Cambodia and elsewhere in Thailand.
In  ﬁ   eld situations, artesunate-meﬂ   oquine failure is 
likely to be worse than in controlled studies because of 
poorer compliance and variations in drug quality. Some 
of the results presented above might have overestimated 
artesunate-meﬂ  oquine therapeutic efﬁ  cacy because 1) 28-
day follow-up is inadequate time to evaluate drugs with a 
long elimination half-life, such as meﬂ  oquine for which up 
to 60% of recrudescence may occur between day 28 and 
day 42 (9), and 2) the current genotyping method is likely 
to misclassify some recrudescence as reinfection because 
of the method’s limited ability to detect minor subpopula-
tions of parasites that carry drug resistance mutations (J. 
J. Juliano, pers. comm.). In our opinion, PCR correction 
to classify recurrent infections is not necessary for a low-
transmission area such as the Cambodia–Thailand border, 
where infection frequently results from occupational expo-
sure in the jungles and patients usually remain at low risk 
for reinfection while in the village during study follow-up.
These treatment failures most likely result from meﬂ  o-
quine resistance rather than artemisinin resistance because 
increased pfmdr1 copy number has been linked most close-
ly with meﬂ  oquine resistance in vivo (10,11). Monitoring 
of in vitro antimalaria drug susceptibility by the Pasteur 
Institute of Cambodia since 2001 also suggests progres-
sive loss of meﬂ  oquine sensitivity in western Cambodia 
(2). Most likely, meﬂ  oquine resistance in this area had al-
ready reached a level too extreme for the drug to be further 
protected by artesunate. To some extent, the development 
of resistance to artesunate-meﬂ  oquine in areas of preexist-
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Figure. Map of the Cambodia–Thailand border showing the town 
of Pailin, Cambodia, and the provinces of Chanthaburi and Trat, 
Thailand; the areas are collectively known as the epicenter of drug-
resistant malaria.
Table. Studies that demonstrated poor artesunate-mefloquine efficacy, Cambodia–Thailand border* 
Reference
Study site, 
country, y  ACT No. patients
Follow-up 
duration, d  Efficacy, % 
Denis et al., 
2006 (5)
Pailin, Cambodia, 
2002
ATS |12 mg/kg in 2 doses on days 0, 1, and 2  
+ MFQ |20 mg/kg in 2 doses on day 0 
70 children
and adults
28 85.7 (PCR-
corrected) 
Vijaykadga et 
al., 2006 (6)
Trat, Thailand, 
2003
ATS 12 mg/kg (maximum 600 mg) in 2 doses 
on days 0 and 1 + MFQ 25 mg/kg (maximum 
1,250 mg) in 2 doses on day 0 
44, age >10 y, 
mostly adults  
28 78.6
Denis et al., 
2006 (5)†
Pailin, Cambodia, 
2004
ATS 12 mg/kg in 2 doses on days 0, 1, and 2 + 
MFQ 25 mg/kg in 2 doses on day 0 
58 children
and adults 
42 79.3 (PCR-
corrected) 
*ACT, artemisinin-based combination therapy; ATS, artesunate; MFQ, mefloquine; day 0, first 24 h of enrollment and start of therapy. 
†Also in this study, increased copy numbers of Plasmodium falciparum multidrug resistance 1 gene were found to be associated with parasite 
recrudescence, and as many as 44% of patients did not clear parasites until after 48 hours. SYNOPSIS
ing meﬂ  oquine resistance mirrors the experience with the 
meﬂ   oquine-sulfadoxine-pyrimethamine combination that 
was introduced to deal with widespread preexisting sulfa-
doxine-pyrimethamine resistance (3).
Fortunately, no clear evidence points to artesunate fail-
ure, although it is possible. No mutations thought to be as-
sociated with artemisinin resistance have been detected in 
Cambodia, and no isolates resistant to artesunate in vitro 
have been found (12). However, the increased parasite clear-
ance times recorded in Pailin are worrisome. In the Pailin 
2004 study, as many as 34% of patients cleared parasites be-
tween 48 and 72 hours, and 10% after 72 hours (9). When 
artesunate was ﬁ  rst introduced in the early 1990s, failure to 
clear parasites by 48 hours was rare among patients with un-
complicated falciparum malaria in southeastern Thailand. 
Additionally, increased copy numbers of pfmdr1 gene have 
recently been shown to be associated with in vitro resistance 
to artemisinin (and to lumefantrine and quinine) (13).
Likely Resistance Factors
Several reasons may explain the emergence of arte-
sunate-meﬂ  oquine resistance on the Cambodia–Thailand 
border. First, the concept of rational therapy is poorly re-
inforced. Improper use of antimalaria drugs based on clini-
cal diagnosis alone or on misdiagnosis as a result of poor 
microscopy technique or interpretation could have acceler-
ated the onset of resistance. In Cambodia, because of poor 
transportation and public health infrastructure, artesunate 
and meﬂ  oquine are made available in the private sector to 
increase patients’ access to the drug. This access, in turn, 
increases the risks that drug quality will be substandard and 
drug use will be uncontrolled (5). Because adherence and 
indication are not adequately emphasized, drugs are con-
sumed in incomplete dosages or for prophylaxis such as 
before a jungle trip. Social marketing helps to control drug 
quality but cannot ensure adherence. 
Although ACT use has been restricted and prescription 
is based on microscopic conﬁ  rmation at government-run 
malaria clinics in Thailand, ACT is less well-controlled in 
Cambodia. Unreliable services and poor diagnostic capa-
bilities at peripheral health facilities further discourage pa-
tients from seeking malaria treatment from the public sec-
tor and encourage self-purchase of drugs. A recent study of 
malaria treatment–seeking behavior in Cambodia showed 
that >80% of the patients initially sought treatment from 
private providers and pharmacies or consumed drugs on 
their own (14).
Second, the short half-life of artesunate relative to that 
of meﬂ  oquine means that tolerance to meﬂ  oquine could de-
velop when treated patients are reinfected (15). Third, the 
malaria parasites in this region could have a unique ability 
to develop resistance to any antimalaria drugs (16); their 
genetics need to be further studied.
Possible Development of New Foci of Resistance
As of 2007, reduced efﬁ  cacy of artesunate-meﬂ  oquine 
was noted in Kampot, a province southwest of Phnom 
Penh (17). Thus, resistant parasites may be spreading. Al-
though no other ACT is immediately ready for ﬁ  eld use, 
the Greater Mekong subregion will soon need alternatives 
to artesunate-meﬂ  oquine.
In sub-Saharan Africa, presumptive treatment with 
ACT may soon become the norm; this drug-use practice 
may similarly promote evolution of resistance. ACT resis-
tance in Africa could be devastating. This concern has been 
raised repeatedly (18,19). Although artesunate-meﬂ  oquine 
is not recommended for African countries, 1 of the ACTs 
now used is the combination of artemether and lumefan-
trine (Coartem; Novartis, Basel, Switzerland); lumefantrine 
is chemically related to meﬂ  oquine. One way to delay the 
emergence of resistance would be to enforce ACT prescrip-
tion based on accurate biological diagnosis.
Conclusions
Studies are now under way to replicate these initial 
ﬁ   ndings on the Cambodia–Thailand border (20). Nev-
ertheless, existing data strongly suggest that artesunate-
meﬂ  oquine resistance exists in this area. This ﬁ  nding is a 
warning message for Africa, where ACT has been used in 
a large scale but not with parallel effort to enhance rational 
therapy. Continued surveillance for ACT resistance should 
be an integral part of any malaria control program that uses 
these drugs.
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